Neuropilin 2

aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

Retrieved on: 
Thursday, June 10, 2021
Integral membrane proteins, Membrane proteins, Transmembrane proteins, Single-pass transmembrane proteins, Transmembrane receptors, Neuropilin 2, Neuropilin, Semaphorin, E-selectin, aTyr Pharma

The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.

Key Points: 
  • The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.
  • Class 3 Semaphorins are an important set of NRP2 ligands, with recent data implicating their role in sustaining chronic inflammation.
  • Details of the abstract and poster presentation are as follows:
    The poster is also available on the aTyr website.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

aTyr Pharma Presents Preclinical Research Highlighting Mechanistic Insights into Tumor Inhibitory Effects of ATYR2810

Retrieved on: 
Wednesday, May 19, 2021
Branches of biology, Medical specialties, Medicine, Neuropilin 2, Immunology, Vascular endothelial growth factor, Monoclonal antibody, aTyr Pharma

ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF.

Key Points: 
  • ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF.
  • ATYR2810 is the first Investigational New Drug (IND) candidate to arise from aTyr\xe2\x80\x99s in-house research program designing monoclonal antibodies to selectively target the NRP2 receptor and its associated signaling pathways.
  • Preclinical data suggest that ATYR2810 could be effective against certain types of solid tumors.
  • aTyr\xe2\x80\x99s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.

aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Achieve Milestones for First Year of Government Grant to Develop Bispecific Antibody Platform

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Medical specialties, Cytokines, Chemokine receptors, Clusters of differentiation, C-C chemokine receptor type 7, CCL21, Angiology, Dendritic cell, Neuropilin 2, Forward-looking statement, Lymphatic system

\xe2\x80\x9cWe continue to learn more about NRP2 as a target for diseases, including immunology and cancer.

Key Points: 
  • \xe2\x80\x9cWe continue to learn more about NRP2 as a target for diseases, including immunology and cancer.
  • In addition, NRP2 modulates interactions between CCL21 and CCR7 potentially impacting homing of dendritic cells to lymphoid organs.
  • All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain.
  • Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.\n'

aTyr Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Thursday, March 11, 2021
Branches of biology, Biology, Cell biology, Neuropilin 2, Single-pass transmembrane proteins, aTyr Pharma, Neuropilin, Aminoacyl tRNA synthetase, Signal transduction, Cell signaling

Details of the poster presentations are as follows:

Key Points: 
  • Details of the poster presentations are as follows:
    Neuropilin-2 (NRP2) is a cell surface receptor that plays a key role in lymphatic development and in regulating inflammatory responses.
  • In many forms of cancer, high NRP2 expression is associated with worse outcomes.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
  • aTyrs research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases.

aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression

Retrieved on: 
Monday, January 25, 2021
Neuropilin 2, Single-pass transmembrane proteins, Neuropilin, Tumor microenvironment, Cancer, aTyr Pharma

These findings support the potential of NRP2 as a target for cancer therapeutics, possibly through the immune regulation of the tumor microenvironment.

Key Points: 
  • These findings support the potential of NRP2 as a target for cancer therapeutics, possibly through the immune regulation of the tumor microenvironment.
  • Our panel of highly specific antibodies selectively targeting NRP2, such as our lead IND candidate ATYR2810, may present differentiated approaches to treating certain aggressive cancers where NRP2 is implicated.
  • Neuropilin-2 (NRP2) is a cell surface receptor that plays a key role in lymphatic development and in regulating inflammatory responses.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

aTyr Pharma Announces Research Collaboration with Medical University of South Carolina

Retrieved on: 
Thursday, October 29, 2020
aTyr Pharma, Neuropilin 2, Cancer, Lung cancer, Neuropilin, Branches of biology, Health, Biology

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has entered into a research collaboration with the Medical University of South Carolina (MUSC).

Key Points: 
  • SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has entered into a research collaboration with the Medical University of South Carolina (MUSC).
  • Dr. Gemmills research focuses on the genetic alteration of genes during lung and kidney cancer development, including the role of Neuropilin-2 (NRP2).
  • Lung cancer is the most common cancer and the leading cause of cancer death among men and women worldwide.
  • The development of new therapeutic strategies, which can enhance the existing therapeutic approaches and reduce or overcome drug resistance, are greatly needed.

aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II

Retrieved on: 
Monday, June 22, 2020
Branches of biology, Medical specialties, Biology, Immunology, Neuropilin 2, Breast cancer, Triple-negative breast cancer, Vascular endothelial growth factor, Neuropilin, Antibody

Poster details data from aTyrs preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies

Key Points: 
  • Poster details data from aTyrs preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies
    may increase sensitivity to chemotherapy in triple-negative breast cancer.
  • Importantly, these antibodies showed differential binding to specific domains of NRP2, selectively inhibiting binding of either VEGF or Sema3F.
  • In combination with chemotherapy, an antibody blocking the VEGF binding site of NRP2 was effective in preventing mammosphere formation in organoids derived from triple-negative breast cancer (TNBC) patients.
  • These results suggest that antibodies targeting NRP2 could potentially be effective in certain types of solid tumors, including breast cancer.